Tamada Satoshi, Ninomiya Noriko, Kitamoto Koichiro, Kato Minoru, Yamasaki Takeshi, Iguchi Taro, Ohmachi Tetsuji, Nakatani Tatsuya
Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka545-8585, Japan.
Department of Urology, Bell Land General Hospital, 500-3 Higashiyama, Naka-ku, Sakai 599-8247, Japan.
J Radiat Res. 2017 Jul 1;58(4):552-558. doi: 10.1093/jrr/rrw119.
We sought to investigate the long-term outcomes after radical prostatectomy (RP) and external-beam radiation therapy (EBRT) for the treatment of localized prostate cancer in Japanese patients. RP and radiation therapy are curative treatments for localized prostate cancer. However, there is controversy around which treatment is superior in Japanese patients. The aim of our retrospective study was to compare the long-term clinical outcomes of each treatment. We retrospectively evaluated the overall survival (OS), cancer-specific survival (CSS) and biochemical failure-free survival (BFS) for patients who had been diagnosed with localized prostate cancer and treated with RP (n = 248) or conventional 2D or 3D-CRT EBRT (n = 182) between 1995 and 2009. The median OS was superior in the RP group compared with that in EBRT group (P < 0.001), although CSS was comparable for both treatment groups; BFS was superior for the EBRT group compared with that for the RP group (P = 0.04). Univariate analysis identified a prostate-specific antigen count (PSA)of ≥20 vs <20 mg/ml, clinical T-stage of the tumor and Gleason score as predictors for CSS. However, multivariate analysis did not identify a factor for CSS. Subgroup analysis was also performed based on clinical T stage, PSA and Gleason score, but there was no difference in each subgroup between RP and EBRT. Both treatments provided satisfactory clinical outcomes in terms of disease control in localized prostate cancer.
我们试图研究根治性前列腺切除术(RP)和外照射放疗(EBRT)治疗日本局限性前列腺癌患者后的长期疗效。RP和放疗是局限性前列腺癌的治愈性治疗方法。然而,对于日本患者哪种治疗更优存在争议。我们这项回顾性研究的目的是比较每种治疗的长期临床疗效。我们回顾性评估了1995年至2009年间被诊断为局限性前列腺癌并接受RP治疗(n = 248)或传统二维或三维适形放疗EBRT治疗(n = 182)患者的总生存期(OS)、癌症特异性生存期(CSS)和无生化失败生存期(BFS)。RP组的中位OS优于EBRT组(P < 0.001),尽管两个治疗组的CSS相当;EBRT组的BFS优于RP组(P = 0.04)。单因素分析确定前列腺特异性抗原计数(PSA)≥20 vs <20 mg/ml、肿瘤的临床T分期和 Gleason评分是CSS的预测因素。然而,多因素分析未确定CSS的相关因素。还根据临床T分期、PSA和Gleason评分进行了亚组分析,但RP和EBRT在各亚组中无差异。就局限性前列腺癌的疾病控制而言,两种治疗均提供了令人满意的临床疗效。